Objective: To determine the prevalence of intrahospital oral benzodiazepine use in the surgical population of a tertiary care centre.
Summary Of Background Data: Oral benzodiazepines used for treating sleep disturbances and anxiety are widely used in the general population. Information regarding benzodiazepine use during hospitalization is scarce.
Methods: A retrospective cohort study was conducted using routinely collected healthcare data in a university hospital in Rotterdam, the Netherlands. 10,896 patients representing 14,928 admissions were included in this cohort, corresponding to all adult surgical patients admitted between September 2018 and September 2022. Median age was 62 (50-72) and 8,761 out of 14928 (58.9%) were male. Main outcome measures were prevalence and incidence of oral benzodiazepines usage during hospitalization.
Results: Prevalence of benzodiazepine administrations in the surgical department was 21.6% out of 14,928 admissions. Median number of tablets given during hospital stay was 3 (1-7). Temazepam (33%), oxazepam (24%) and zopiclone (19%) were prescribed most. Female patients were more likely to have been administered a benzodiazepine, with an adjusted odds ratio of 1.09 (95% confidence interval 1.002 to 1.19). Benzodiazepine administration during admission was positively associated with higher 30-day surgical readmission, with an adjusted odds ratio of 1.37 (1.22 to 1.54).
Conclusions: In this study, one fifth of patients admitted to surgical departments were administered oral benzodiazepines for sleep disturbances and anxiety. Future research and policies should focus on finding and implementing effective non-pharmacological methods for perioperative sleep disturbances and anxiety.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/SLA.0000000000006647 | DOI Listing |
Ann Surg
January 2025
Department of Anaesthesiology, Erasmus Medical Centre 3015 GD, Rotterdam, The Netherlands.
Objective: To determine the prevalence of intrahospital oral benzodiazepine use in the surgical population of a tertiary care centre.
Summary Of Background Data: Oral benzodiazepines used for treating sleep disturbances and anxiety are widely used in the general population. Information regarding benzodiazepine use during hospitalization is scarce.
Clin Kidney J
January 2025
Faculty of Biology, Medicine and Health, School of Medical Sciences, University of Manchester, Oxford Road, Manchester, UK.
Background And Hypothesis: Mild cognitive impairment and dementia (CI) are common in patients with CKD. We aim to clarify whether and how CKD and CI coexistence increases adverse health outcomes.
Methods: This retrospective observational cohort study was conducted on CKD patients (stages 3-5) from the TriNetX platform.
Sleep
January 2025
Complete HEOR Solutions (CHEORS), Chalfont, PA, USA.
Study Objectives: This study assessed the utilization of potentially inappropriate medications (PIM) including oral sedative-hypnotic and atypical antipsychotic (OSHAA), healthcare resource utilization (HCRU), and costs among elderly individuals with insomnia and in the subpopulation with Alzheimer's Disease (AD) who also had a diagnosis of insomnia.
Methods: Using claims database containing International Classification of Diseases, 10th Revision (ICD-10) codes, the cohort included individuals aged ≥ 65 with incident insomnia (EI, N=152,969) and AD insomnia subpopulation (ADI, N=4,888). Proportion of patients utilizing atypical antipsychotics or oral sedative-hypnotic medications, namely z-drugs, benzodiazepines, doxepin, Dual Orexin Receptor Antagonists (DORAs), and melatonin agonists, were assessed.
Front Neurosci
January 2025
Kontigo Care AB, Uppsala, Sweden.
Background: It is known that illicit and prescribed drugs impact pupil size, eye movement and function. Still, comprehensive quantitative evaluations under known ambient light conditions are lacking, when smartphones are used for monitoring.
Methods: In this clinical study (NCT05731999), four medicinal products with addiction risks were administered to 48 subjects (18-70 years old, all with informed consent, 12 subjects per drug).
Spec Care Dentist
January 2025
Department of Periodontology, Faculty of Dental Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Aims: To assess and compare the effectiveness of pharmacological and cognitive-behavioral modalities-behavioral methods (BM), nitrous oxide inhalation sedation (NOIS), and premedication with Diazepam-for alleviating anxiety during dental treatment, using completed treatment sessions and adverse outcomes as indicators.
Methods And Results: For 239 patients (515 dental records), 18-53 y/o, who underwent dental treatments under anxiety reduction measures, sessions under NOIS were categorized as "nitrous group" (456 sessions) versus premedication with Diazepam or behavioral strategies (control, 59 sessions). Outcomes were completed treatment sessions considering demographic and clinical parameters, and adverse outcomes during and between sessions.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!